February 15, 2010 (Vol. 30, No. 4)
Vi Chu Ph.D. R&D manager EMD Millipore
Review of Opportunities and Challenges in this Rapidly Expanding Field of Study
The ability to reprogram somatic cells to generate induced pluripotent stem (iPS) cells has generated tremendous interest and discussion since iPS cells were first produced from mouse cells in 2006 and human cells in 2007.
The reversion of differentiated cells to a state resembling embryonic stem cells offers a wealth of opportunities for disease researchers. Interest in iPS cells is expanding rapidly beyond the domain of stem cell experts to researchers modeling complex diseases in vitro and pursuing novel therapeutics.
With iPS cell technology, you can now take a skin biopsy from a patient with a genetic disease such as familial Alzheimer or Lou Gehrig disease and turn their somatic cells into stem cells, explains Chad Cowan, Ph.D., of the Harvard Stem Cell Institute. You can then take those stem cells and turn them into cell types that might be affected in the disease.
Along with the opportunities offered by iPS cells, practical challenges still abound. Culturing stem cells relies on both science and art and defining just what exactly constitutes a stem or iPS cell is stimulating a good deal of discussion.
Having standards for iPS cells could help define the differences between these murine embryonic stem cells and their induced counterparts.
Dr. Cowans lab is using iPS cells to support studies of obesity and metabolic disorders. While the lab can easily obtain fat cells from patients, these cells cant be cultured over the long term. We can keep the fat cells alive for a short period of time but that only allows us to do a one-time endpoint assay. It doesnt allow us to tease out the complexities of what might be going wrong in a patient with a metabolic disorder. The ability to make patient-specific fat cells from iPS cells completely changes the game.
With iPS cells, the lab can conduct dozens of assays to identify differences in fat cells from a person with a metabolic disorder such as type 2 diabetes versus a person with normal body weight or someone without diabetes. The ability to take a single genotype and potentially make any of the tissues that might be involved in a metabolic disorder such as hypothalamus, pancreatic beta cells, and hepatocytes, could lead to powerful disease models.
In his lab at the University of California, Santa Barbara, Dennis Clegg, Ph.D., is using iPS cells as one tool to study the loss of vision in age-related macular degeneration (AMD). In AMD, the degeneration of retinal pigment epithelial (RPE) cells appears to cause the death of neighboring rods and cones in the macular region of the central retina.
Dr. Cleggs lab is evaluating the use of iPS-derived RPE cells to treat AMD and using iPS cell lines to create ocular cells, which can be used to study how the eye develops. The real utility of iPS cells is that you can study human cells and processes in ways you couldnt do before, notes Dr. Clegg.
iPS cells, in particular those that are human-derived, can be challenging to culture especially for those researchers who havent previously worked with stem cells. The challenges they present are similar to those encountered when culturing human embryonic stem cells, including:
For researchers who havent previously cultured stem cells, I suggest first working with mouse-derived iPS cells. These cells tend to be more robust than human cells and conditions for successful culture are well defined. Many researchers first test their hypotheses using mouse iPS cells and then transition to a human model system.
The technology to create iPS cells is evolving rapidly. The first studies reporting the creation of iPS cells used retroviral vectors to integrate a set of DNA transcription factors directly into the somatic cell genome. Upon activation, these genes convert the cells from their adult, differentiated status to an embryonic-like state. This process required multiple retroviral vectors in order to insert four different viruseseach vector delivering one reprogramming gene into the somatic cells DNA.
Since these first studies were published, researchers have been seeking ways to reprogram somatic cells without using retroviral vectors and avoiding use of transcription factors such as c-Myc that are known oncogenes. Viral delivery of transcription factors can also disrupt normal gene expression when the vectors integrate into the genome. The high number of genomic integrations15 to 20that typically occur when multiple viruses are used for reprogramming poses a safety risk if the cells are to be used for therapeutic purposes.
Recently, Boston University scientists developed a highly efficient method for creating iPS cells from mouse fibroblasts using a single viral vector instead of the multiple viruses typically required for reprogramming. Four commonly used vectors are incorporated into a single lentiviral vector containing all four genes.
If iPS cells are to be used for therapeutic purposes, permanent integration of transcription factors into the genome becomes a problem. Alternative approaches to reprogramming include use of adenoviral delivery as the adenovirus does not integrate into the genome and transient transfection with transcription factors. Ultimately, it may be possible to use proteins or small molecules to direct the reprogramming process.
The rapid development and continued evolution of iPS technology has sparked discussions about the need for establishing standards to guide the field.
As researchers seek new methods to create iPS cells without genetic modification and the use of these cells to develop disease models continues to expand rapidly, questions arise as to whether these cells have the same properties and potential as embryonic stem cells. How can a researcher know for certain that he or she has generated iPS cells? Is there a minimum set of criteria for assessing whether a somatic cell is fully pluripotent or only partially reprogrammed?
Adding to this complexity, researchers also seek to understand the variation between iPS cell lines derived from a common somatic source.
Dr. Cleggs lab is looking at the similarities and differences between iPS cell lines derived from human fetal RPE cells. The question we were trying to address, describes Dr. Clegg, is if we take those cells down to iPS cells and just let them spontaneously differentiate, will they have some sort of epigenetic memory and tend to re-differentiate back into RPE or something else?
The first line we looked at snapped back in large quantities to RPE cells, reports Dr. Clegg. But each subsequent line we looked at was different. Thats an important lesson for people to understandeach iPS line thats generated is slightly different, just like each embryonic stem cell line is slightly different. They have different propensities for differentiation. They may have different epigenetics. They may have different expression patterns.
Were still learning to define what is the best iPS cell, notes Dr. Cowan. The best function identically to an embryonic stem cell. It remains pluripotent, expands, and self-renews and it can differentiate into the types of tissues youre interested in.
An article by Maherali and Hochedlinger (Cell Stem Cell Protocol Review, December 4, 2008) suggests a minimal set of criteria that should be fulfilled in order to ascertain that a genuine iPS cell has been generated. The criteria include:
With human iPS cells, pluripotency can be assessed based on teratoma formation, which is a specific type of tumor containing cells from all three germ layers.
Researchers are also probing the similarity of iPS cell and embryonic cells through microarray studies, high-throughput sequencing, assessment of DNA methylation status at pluripotent cell specific genes, and by examining a range of protein biomarkers.
As our understanding of the similarities and differences between iPS cells and embryonic stem cells grows, new tools to identify and compare these cell types are needed. For example, live-cell imaging can be used to distinguish between human iPS cells and partially reprogrammed cells.
While standards provide a good basis of comparison, Dr. Cowan suggests that standards can be restrictive. The standards are naturally evolving. We certainly need to maintain a minimum standard and recognize the standard will change over time. Within a year or two, there will probably be a new set of guidelines available. But there may be times when you may not want to make something that is an embryonic cell.
In fact, it may be more to your advantage to somehow uniquely trap a cell so that it is lineage-committed to something that can replicate in culture indefinitely but really only thinks of itself as lung, for example, and so would only ever differentiate back to lung cell types.
While a great deal remains to be learned about iPS cells, they represent a powerful new research tool. In addition to their potential impact on the field of regenerative medicine, use of iPS cells to dissect complicated diseases at the cellular level will provide valuable new insights supporting drug discovery. As we learn more about the nature of iPS cells, standards will certainly evolve and new tools will become available to facilitate efficient creation and routine culture.
Vi Chu, Ph.D. (firstname.lastname@example.org), is R&D manager, stem cell/cell biology at Millipore.
Here is the original post:
Induced Pluripotent Stem Cell Overview - genengnews.com
- Generation of self-organized sensory ganglion organoids and retinal ganglion cells from fibroblasts - Science Advances - May 30th, 2020
- Hesperos Human-on-a-Chip System Used to Model Preclinical Stages of Alzheimer's Disease and Mild Cognitive Impairment - Business Wire - May 30th, 2020
- AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A -... - May 30th, 2020
- In Vitro Toxicology Testing Market to Grow at Robust CAGR in the COVID-19 Lockdown Scenario - Cole of Duty - May 30th, 2020
- Study: Heart Problems in SMA May Be Tied to Calcium Dysregulation - SMA News Today - May 25th, 2020
- Stem Cell and Regenerative Medicine Market is Expected to Garner USD 14745.7 Million by The End of 2024 By Recording a CAGR of 4.8% (Impact Analysis... - May 20th, 2020
- Induced Pluripotent Stem Cell (iPS Cell) Applications in 2020 - May 16th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 16th, 2020
- Induced Pluripotent Stem Cells Market 2020: Growing Tends ... - May 16th, 2020
- Cell Therapy Shows Promise in Parkinson's - MedPage Today - May 14th, 2020
- Induced Pluripotent Stem Cells Market Growth by Top Companies, Trends by Types and Application, Forecast to 2026 - Cole of Duty - May 14th, 2020
- Citius Announces Data on NoveCite Mesenchymal Stem Cells (NC-MSCs) to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual... - May 14th, 2020
- Novel CAR NK-cell technology could lead to new treatments for lupus, other incurable diseases - Stockhouse - May 14th, 2020
- 2020 Insights on the Worldwide Induced Pluripotent Stem Cell Industry - ResearchAndMarkets.com - Business Wire - May 12th, 2020
- Cell and Gene Therapy Catapult links with Japan's CiRA Foundation - PharmaTimes - May 12th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market 2020 | Growth Drivers, Challenges, Trends, Market Dynamics and Forecast to 2026 - Cole of Duty - May 9th, 2020
- Induced Pluripotent Stem Cells Market Overview With Detailed Analysis, Competitive Landscape, Forecast to 2026 - Weekly Wall - May 9th, 2020
- Mogrify strikes deal with US biopharma Sangamo Therapeutics - Cambridge Independent - April 28th, 2020
- How could Covid-19 and the body's immune response affect the brain? - MIT News - April 28th, 2020
- Induced Pluripotent Stem Cells Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 28th, 2020
- FDA Expediting Accelerated Development of Novel Therapies for COVID-19 - Yahoo Finance - April 28th, 2020
- GLOBAL TOOTH REGENERATION MARKET: INDUSTRY ANALYSIS AND FORECAST (2020-2027) - MR Invasion - April 28th, 2020
- Insights on the Cell Expansion Industry in North America to 2027 - by Product, Cell Type, Application, End-user and Country - Yahoo Finance - April 26th, 2020
- Induced pluripotent stem cells and CRISPR reversed diabetes in mice - Drug Target Review - April 24th, 2020
- Reversing diabetes with CRISPR and patient-derived stem cells - FierceBiotech - April 24th, 2020
- The integrated stress response: From mechanism to disease - Science Magazine - April 24th, 2020
- Diabetes reversed in mice with genetically edited stem cells derived from patients - Washington University School of Medicine in St. Louis - April 23rd, 2020
- Business News: Induced Pluripotent Stem Cells Market Growth, Analysis and Forecast 2020 to 2025 | BlueRock Therapeutics, Corning Life Sciences, EMD... - April 23rd, 2020
- Stem Cell Therapy Market: Industry Size, Market Status, Influencing Factors, Competition, Outlook & Forecasts to 2027 - Cole of Duty - April 23rd, 2020
- Induced Pluripotent Stem Cells Market Analysis With Key Players, Applications, Trends And Forecasts To 2026 - Surfacing Magazine - April 21st, 2020
- Induced Pluripotent Stem Cells Market 2019 analysis, size, top companies, share, strategies and forecast to 2026 - WhaTech Technology and Markets News - April 21st, 2020
- Cell Therapies Can Revolutionize Treatment, Automation Needed to Scale Production - ENGINEERING.com - April 15th, 2020
- Lung epithelium model being tested as a platform for COVID-19 research - Drug Target Review - April 11th, 2020
- Fate Therapeutics' IO Collaboration with Janssen Could Yield Company $3 Billion - Clinical OMICs News - April 11th, 2020
- Induced Pluripotent Stem Cells Market Key Players, Size, Share, Growth, Trends, Analysis And Forecast 2025 - Science In Me - April 9th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market in 2020: Industry Overview on Global Size, Share, Future Trends, Segmentation, Demands, and Top Players... - April 9th, 2020
- Evotec Makes Move into Gene Therapy with Takeda... - Labiotech.eu - April 9th, 2020
- Induced Pluripotent Stem Cell Research Pros And Cons ... - April 2nd, 2020
- Evotec Expands Its IPSC-Based Cell Therapy Platform Evocells Through Licensing Agreement with panCella - Benzinga - April 2nd, 2020
- Citius Signs Option With Novellus To License Novel Stem-Cell Therapy For ARDS - Nasdaq - April 2nd, 2020
- Anti-IL-6 Monoclonal Antibodies as Antiarrhythmic Treatment for HF - The Cardiology Advisor - April 2nd, 2020
- A New NK Cell-based Immunotherapy For Cancer Treatment - Health News Today - March 24th, 2020
- Coriell Institute for Medical Research Awarded $8.6 Million Biobanking Contract from National Institute on Aging - Newswise - March 18th, 2020
- Stem cells to help the heart - Science Magazine - March 12th, 2020
- Induced Pluripotent Stem Cells Market Expected to Witness the Highest Growth 202 - ITResearchBrief.com - March 12th, 2020
- SpaceX Dragon cargo ship, the last to be caught by robot arm, arrives at space station - Space.com - March 11th, 2020
- Notice of Capital and Business Alliance between Heartseed and MEDIPAL HOLDINGS | DNA RNA and Cells | News Channels - PipelineReview.com - March 11th, 2020
- NanoSurface Bio Executes Exclusive License of Heart-on-Chip Technology Launched Into Space - Business Wire - March 9th, 2020
- Eye health: Testing the safety of stem cell therapy for age-related macular degeneration - Open Access Government - March 9th, 2020
- Despite Pro-Life Claims, Stem Cell Therapy Has Very Real Benefits and Should Be Accessible - Patheos - March 6th, 2020
- Little Tissue, Big Mission: Beating Heart Tissues to Ride Aboard The ISS - Newswise - March 4th, 2020
- SpaceX set to launch Falcon 9 rocket and Dragon capsule from Cape Canaveral this week - Florida Today - March 4th, 2020
- SpaceX Targeting March 6 for Launch of its 20th Resupply Mission to International Space Station | - SpaceCoastDaily.com - February 29th, 2020
- The European Bank of Induced Pluripotent Stem Cells: Five Years of Progress - Technology Networks - February 28th, 2020
- New study identifies trigger that turns dormant cancer stem cells into active ones - PR Web - February 26th, 2020
- Induced Pluripotent Stem Cells (iPSCs) Market in 2020: Global Industry Size, Demand, Growth & Development, Trends, Insights and Forecast until... - February 25th, 2020
- Improving shoes, showers, 3D printing: research launching to the Space Station - Space Daily - February 21st, 2020
- Argentinian cultured meat supplier on its 'all-in-one' cell line: 'We offer cells that can grow fast and reduce costs' - FoodNavigator-Latam - February 20th, 2020
- Building a 'doomsday vault' to save the kangaroo and koala from extinction - CNET - February 19th, 2020
- Surge in the Adoption of Stem Cell-Derived Cells to Fuel the Growth of the Stem Cell-Derived Cells Market Through the Assessment Period 2019 2029 -... - February 17th, 2020
- Global Induced Pluripotent Stem Cells Market to Achieve more Profitability Ratio between 2020-2025 - Chronicle 99 - February 16th, 2020
- Cell-based meat in focus: In conversation with Meatable, Finless Foods, New Age Meats - FoodNavigator-USA.com - February 11th, 2020
- Research could be step toward lab-grown eggs and sperm to treat... - ScienceBlog.com - February 10th, 2020
- First dual stem cell therapy jointly developed by City University of Hong Kong brings new hope for cardiac repair - QS WOW News - February 10th, 2020
- Chromatin accessibility analysis reveals regulatory dynamics of developing human retina and hiPSC-derived retinal organoids - Science Advances - February 10th, 2020
- AgeX Therapeutics to Collaborate with University of California, Irvine on Neural Stem Cell Research Program for Huntingtons Disease and Other... - February 4th, 2020
- 2020 Induced Pluripotent Stem Cells (iPSCs) Study: Global Markets, Technologies, Applications and Companies - Yahoo Finance - February 2nd, 2020
- Can Parkinsons be prevented as it stealthily develops? - Big Think - February 2nd, 2020
- Unpicking the proteome in single cells - Science Magazine - February 2nd, 2020
- Kyoto University team gets OK from ministry for plan to transplant iPS-derived cartilage into knee joints - The Japan Times - January 25th, 2020
- The Kyoto University team's plan to transplant iPS cartilage into knee joints is OK - gotech daily - January 25th, 2020
- Get rid of the ache within the nerves discovered with the following pointers, learn - Sahiwal Tv - January 25th, 2020
- Astellas and Adaptimmune team up in CAR-T development - European Biotechnology - January 15th, 2020
- Stem Cell Therapy Market Rising Demand for Digitization in Organizations and Growth till 2027 - Galus Australis - January 15th, 2020
- Allele and Astellas Enter into an Expanded License for the Development of iPSC Lines - Yahoo Finance - January 15th, 2020
- Researchers have managed to bio-print a functional mini-liver in 90 days - FLWL News - January 15th, 2020
- CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC derived CAR NK Therapeutics -... - January 10th, 2020
- Stem Cells Market Segmentation and Analysis Report, 2025 - Food & Beverage Herald - January 10th, 2020
- Stem Cell Therapy Market Robust Growth Counted to 2025 - Instanews247 - January 10th, 2020
- The Top Biotech Trends We'll Be Watching in 2020 - Singularity Hub - January 10th, 2020